Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor (evolocumab) plus atorvastatin for acute symptomatic intracranial arterial stenosis
ChiCTR2400081186Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in cerebrovascular disease, Cerebral atherosclerotic stenosis (ICAD), ischemic stroke and 1 more (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Atherosclerotic plaque morphological assessment. Started Feb 2024; status: recruiting.
02
Drugs
evolocumab
03
Conditions
cerebrovascular diseaseCerebral atherosclerotic stenosis (ICAD)ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2400081186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081186.